The field of biotechs pursuing new interleukin-2 cancer immunotherapies is filled with companies engineering different versions of that signaling protein. Avenge Bio CEO Mike Heffernan said his startup stands apart with a cell therapy that produces human IL-2 that could offer advantages compared to engineered versions of that protein.
